Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

World AIDS Vaccine Day 2024: Prophylactic vaccines in phase II development hold potential to reduce epidemic burden, says GlobalData

World AIDS (acquired immunodeficiency syndrome) Vaccine Day, also known as HIV (human immunodeficiency virus) Vaccine Awareness Day, takes place annually on 18 May. The National Institute of Allergy and Infectious Diseases (NIAID) leads the observance, educating the public on the importance of HIV prevention and the significance of vaccine research, and acknowledging the contributions of […]
Read more

Roche challenges Regeneron and Bayer’s position as industry leaders within wAMD, DME and DR spaces, says GlobalData

Roche’s Vabysmo (faricimab) is in the spotlight following its promising Q1 2024 sales figures. Vabysmo, a vascular endothelial growth factor (VEGF) inibitior and angiopoietin-2 (Ang-2) inhibitor therapy, is indicated for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). This presents a looming challenge to Regeneron and […]
Read more

Anticipation builds as Insmed bronchiectasis therapy brensocatib nears Phase III completion, observes GlobalData

Insmed is in the spotlight over the past few years for its pipeline agent, brensocatib, which has previously shown promising Phase II results, generating anticipation within the medical community ahead of their Phase III results for the treatment of bronchiectasis. The positive outcomes could pave the way for regulatory approval, potentially transforming the therapeutic landscape […]
Read more

Three BiTEs set to disrupt relapsed/recurrent multiple myeloma space with $9 billion sales by 2030, says GlobalData

Recent developments in the field of bispecific T-cell engagers (BiTEs) have led to the approval of three therapies for relapsed/recurrent multiple myeloma (RRMM): Elrexfio (elranatamab) developed by Pfizer, Tecvayli (teclistamab) and Talvey (talquetamab) developed by Johnson & Johnson. Clinical data of the three have been surprising, surpassing previously anticipated response rates. With an ever-growing number […]
Read more

Cell and gene manufacturers benefit from surge in FDA drug approvals, says GlobalData

2023 marked a significant upsurge in FDA approvals, particularly for groundbreaking treatments such as cell and gene therapies. This surge highlights not just advancements in medical technology but also provides substantial opportunities for manufacturers specializing in these cutting-edge therapies. Looking ahead to 2024-25, the pharmaceutical industry braces for challenges marked by increasing drug approvals, innovative […]
Read more

ESCMID Global 2024 echoes multidisciplinary calls to action, finds GlobalData

Working towards a multidisciplinary approach to navigate the future of infectious diseases has been a key theme at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global* 2024 congress. Key concerns such as climate change and antimicrobial resistance (AMR) were underscored, emphasizing the need for collaborative efforts beyond traditional medical realms. Initiatives […]
Read more

APAC leads in asthma clinical trials between 2019-2023, says GlobalData

The Asia-Pacific (APAC) region is leading in clinical trials in Asthma between 2019-2023, with China, India, and South Korea among the top countries in this space, according to GlobalData, a leading data and analytics company. According to GlobalData’s Clinical Trials Database, during 2019-23, 51.8% of asthma trials were initiated in the APAC region. China emerged […]
Read more

Chinese companies lead ADC development pipeline, reveals GlobalData

Antibody drug conjugates (ADCs) are a rapidly growing therapeutic class, and Chinese companies are leading the ADC trend, accounting for half of the top 10 developers as they seek to capitalize on potential returns. The significant level of Chinese innovation and presence within the new cancer therapy space underlies the country’s emergence as a key […]
Read more

Samsung Biologics set to thrive if BIOSECURE bill passes in US, says GlobalData

The biopharmaceutical industry has been buzzing over the US government’s unveiling of the BIOSECURE bill. Introduced in the House of Representatives in January 2024, the bill mainly aims to restrict federal government funding and/or partnerships with a few Chinese companies deemed a threat to national security. Samsung Biologics, a South Korean biopharmaceutical contract development, and […]
Read more

Biohaven’s Taldefgrobep alfa could target broad SMA patient population, says GlobalData

At the American Academy of Neurology (AAN) 2024 Annual Meeting, Biohaven presented its Phase III RESILIENT (NCT05337553) trial design, which investigates the efficacy and safety of taldefgrobep alfa in patients with spinal muscular atrophy (SMA). Taldefgrobep alfa is a myostatin inhibitor in development as an adjunctive therapy alongside marketed therapies to offer symptomatic relief to […]
Read more

Oligonucleotides and mRNA vaccines dominate in strategic alliances for RNA-therapies in major APAC countries, says GlobalData

RNA-based therapies have already proven and will continue to play an integral role in the development of novel therapeutic agents for diseases in the future. Against this backdrop, biopharmaceutical companies based in the major Asia-Pacific (APAC) countries (Australia, China, Japan, and South Korea) entered into significant partnerships to develop RNA-based therapies in the last five […]
Read more

APPLAUSE-IgAN trial interim analysis highlights Novartis’ potential to differentiate in IgAN space, says GlobalData

At this year’s World Congress of Nephrology, positive results were presented from Novartis’s pre-specified interim analysis of the Phase III APPLAUSE-IgAN clinical trial. According to the analysis, the use of Fabhalta (iptacopan) was shown to reduce proteinuria in patients with immunoglobulin A (IgA) nephropathy (IgAN) compared to placebo. The drug potentially fills an unmet need […]
Read more

Radius Pharmaceuticals’ Tymlos will have to face highly competitive osteoporosis market despite positive results, says GlobalData

Radius Pharmaceuticals unveiled real-world evidence at the recently held World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, demonstrating increased efficacy of Tymlos (abaloparatide) therapy in reducing hip and non-vertebral fractures compared to teriparatide in women aged 50 years and older. Despite positive results, Tymlos will have to face a highly competitive osteoporosis market, according to […]
Read more

AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 billion in sales by 2027, says GlobalData

In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca/Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy. Since then, the PARP inhibitors market has made significant strides, but Lynparza maintains its dominance with projected global sales […]
Read more
1 … 19 20 21 22 23 … 108